Synchron is a pioneering company in the realm of implantable brain-computer interfaces, leading the way with groundbreaking innovations. Its flagship product, the stentrode, holds the distinction of being the first commercial implantable brain-computer interface to gain FDA IDE approval for human clinical trials. Launched in 2012, Synchron has focused on developing a solution that circumvents the need for invasive open brain surgery. Instead, their technology relies on a minimally invasive procedure, making it a revolutionary step forward in the field. This milestone not only enhances the safety profile of brain-computer interfaces but also opens up new possibilities for the future of neuroscience and medical technology.
